Impact of Johnson & Johnson Opioid Ruling on Pharmaceutical Industry

With the recent opioid ruling against Johnson & Johnson, how does this impact the rest of the pharmaceutical industry? Chris Meekins, a Healthcare Policy Analyst at Raymond James, gives us his insights.

This entry was posted in Biotech & Pharmaceuticals, Crime and Law, Health Care, NBR Show Clips. Bookmark the permalink.

Leave a Reply